@article{PAR00011679,
  title = {{H}igher frequency of genetic variants conferring increased risk for {ADR}s for commonly used drugs treating cancer, {AIDS} and tuberculosis in persons of {A}frican descent},
  author = {{A}minkeng, {F}. and {R}oss, {C}. {J}. {D}. and {R}assekh, {S}. {R}. and {B}runham, {L}. {R}. and {S}istonen, {J}. and {D}ube, {M}. {P}. and {I}brahim, {M}. and {N}yambo, {T}. {B}. and {O}mar, {S}. {A}. and {F}roment, {A}lain and {B}odo, {J}. {M}. and {T}ishkoff, {S}. and {C}arleton, {B}. {C}. and {H}ayden, {M}. {R}.},
  editor = {},
  language = {{ENG}},
  abstract = {{T}here is established clinical evidence for differences in drug response, cure rates and survival outcomes between different ethnic populations, but the causes are poorly understood. {D}ifferences in frequencies of functional genetic variants in key drug response and metabolism genes may significantly influence drug response differences in different populations. {T}o assess this, we genotyped 1330 individuals of {A}frican (n=372) and {E}uropean (n=958) descent for 4535 single-nucleotide polymorphisms in 350 key drug absorption, distribution, metabolism, elimination and toxicity genes. {I}mportant and remarkable differences in the distribution of genetic variants were observed between {A}fricans and {E}uropeans and among the {A}frican populations. {T}hese could translate into significant differences in drug efficacy and safety profiles, and also in the required dose to achieve the desired therapeutic effect in different populations. {O}ur data points to the need for population-specific genetic variation in personalizing medicine and care.},
  keywords = {pharmacogenomic diversity ; genetic ancestry ; drug response ; {ADR}s ; {AFRIQUE} ; {EUROPE}},
  booktitle = {},
  journal = {{P}harmacogenomics {J}ournal},
  volume = {14},
  numero = {2},
  pages = {160--170},
  ISSN = {1470-269{X}},
  year = {2014},
  DOI = {10.1038/tpj.2013.13},
  URL = {https://www.documentation.ird.fr/hor/{PAR}00011679},
}